Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase

References

• BuchdungerEZimmermannJMettHSelective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine classProc Natl Acad Sci U S A199592255825627708684
   PubMed Web of Science ®Google Scholar
• DrukerBJTamuraSBuchdungerEEffects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cellsNat Med199625615668616716
   PubMed Web of Science ®Google Scholar
• HeinrichMCGriffithDJDrukerBJInhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitorBlood20009692593210910906
   PubMed Web of Science ®Google Scholar
• DeiningerMWO’BrienSGFordJMDrukerBJPractical management of patients with chronic myeloid leukemia receiving imatinibJ Clin Oncol2003211637164712668652
   PubMed Web of Science ®Google Scholar
• DrukerBJGuilhotFO’BrienSGFive-year follow-up of imatinib therapy for chronic-phase chronic myeloid leukemiaN Engl J Med20063552408241717151364
   PubMed Web of Science ®Google Scholar
• MughalTIGoldmanJMOptimal management of patients with newly diagnosed chronic phase chronic myeloid leukemia in 2007Clin Lymphoma Myeloma20077338339
   Google Scholar
• HochhausAO’BrienSGGuilhotFSix year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaLeukemia20092131054106119282833
   PubMed Web of Science ®Google Scholar
• KantarjianHTalpazMO’BrienSHigh dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemiaBlood20041032873287815070658
   PubMed Web of Science ®Google Scholar
• HughesTPBranfordSWhiteDLImpact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapyBlood20081123965397318768781
   PubMed Web of Science ®Google Scholar
• CortesJEBaccaraniMGuilhotFPhase III. Randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity studyJ Clin Oncol20102842443020008622
   PubMed Web of Science ®Google Scholar
• KerkelaRGrazetteLYacobiRCardiotoxicity of the cancer therapeutic agent imatinib mesylateNat Med20061290891616862153
   PubMed Web of Science ®Google Scholar
• SchifferCABCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemiaN Engl J Med200735725826517634461
   PubMed Web of Science ®Google Scholar
• AtallahEKantarjianHCortesJIn reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’Nat Med20071314 author reply 15–16.17206119
   PubMed Web of Science ®Google Scholar
• RostiGMartinelliGBaccaraniMIn reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’Nat Med20071315 author reply 15–16.17206121
   PubMed Web of Science ®Google Scholar
• SchmidingerMZielinskiCCVoglUMCardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinomaJ Clin Oncol2008265204521218838713
   PubMed Web of Science ®Google Scholar
• ParkYHParkHJKimBSBNP as a marker of the heart failure in the treatment of imatinib mesylateCancer Lett2006243162216388897
   PubMed Web of Science ®Google Scholar
• AtallahEDurandJBKantarjianHCortesJCongestive heart failure is a rare event in patients receiving imatinib therapyBlood20071101233123717449798
   PubMed Web of Science ®Google Scholar
• RibeiroALMarcolinoMSBittencourtHNAn evaluation of the cardiotoxicity of imatinib mesylateLeuk Res2008321809181418495246
   PubMed Web of Science ®Google Scholar
• PerikPJRikhofBde JongFAResults of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicityAnn Oncol20081935936117962203
   PubMed Web of Science ®Google Scholar
• TiribelliMColatuttoAMarinLBrain natriuretic peptide level as marker of cardiac function in imatinib-treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapyAm J Hematol20088351751818306359
   PubMed Web of Science ®Google Scholar
• BermanENicolaidesMMakiRGAltered bone and mineral metabolism in patients receiving imatinib mesylateN Engl J Med20063542006201316687713
   PubMed Web of Science ®Google Scholar
• LiuFMalavalLAubinJEGlobal amplification polymerase chain reaction reveals novel transitional stages during osteoprogenitor differentiationJ Cell Sci20031161787179612665559
   PubMed Web of Science ®Google Scholar
• HockJMCanalisEPlatelet-derived growth factor enhances bone cell replication, but not differentiated function of osteoblastsEndocrinology1994134142314288119182
   PubMed Web of Science ®Google Scholar
• FiedlerJEtzelNBrennerRETo go or not to go: migration of human mesenchymal progenitor cells stimulated by isoforms of PDGFJ Cell Biochem20049399099815389881
   PubMed Web of Science ®Google Scholar
• GreyAO’SullivanSReidIRBrowettPImatinib mesylate, increased bone formation, and secondary hyperparathyroidismN Engl J Med20063552494249517151376
   PubMed Web of Science ®Google Scholar
• O’SullivanSHorneAWattieDDecreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinibJ Clin Endocrinol Metab2009941131113619174494
   PubMed Web of Science ®Google Scholar
• TibulloDGiallongoCLa CavaPEffects of imatinib mesylate in osteoblastogenesisExp Hematol20093746146819302920
   PubMed Web of Science ®Google Scholar
• FitterSDewarALKostakisPLong-term imatinib therapy promotes bone formation in CML patientsBlood20081112538254718042796
   PubMed Web of Science ®Google Scholar
• FrédéricMBaruchelAGuilhotJImatinib is efficient but has a negative impact on growth in children with previously untreated chronic myelogenous leukemia (CNL) in early chronic phase (CP): results of the French National Phase IV trial ASH proceedings; 2009; [Abstract 863].
   Google Scholar
• SchwartzbergPLStallAMHardinJDMice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populationsCell199165116511752065353
   PubMed Web of Science ®Google Scholar
• AultPKantarjianHO’BrienSPregnancy among patients with chronic myeloid leukemia treated with imatinibJ Clin Oncol2006241204120816446320
   PubMed Web of Science ®Google Scholar
• PyeSMCortesJAultPThe effects of imatinib on pregnancy outcomeBlood20081115505550818322153
   PubMed Web of Science ®Google Scholar
• SeymourJFGriggAReynoldsJTwo year data from a prospective safety study analyzing the consequences of imatinib mesylate inhibition of sensitive kinases other than bcr-abl in patients with previously untreated chronic phase CML [abstract]Blood20061082147a
   Web of Science ®Google Scholar
• MartinHvan der KuipHeikoWalterEATherapeutic options for chronic myeloid leukemia: focus on imatinibTher Clin Risk Manag2008416318718728706
   PubMedGoogle Scholar
• Gambacorti-PasseriniCTornaghiLCavagniniFGynaecomastia in men with chronic myeloid leukaemia after imatinibLancet20033611954195612801741
   PubMed Web of Science ®Google Scholar
• HawkKHeung-MoonCMin-HeeRTae-WonKHee-JungSSo-EunKConcurrent male gynecomastia and testicular hydrocele after imatinibmesylate treatment of a gastrointestinal stromal tumorJ Korean Med Sci20052051251515953881
   PubMed Web of Science ®Google Scholar
• MannavolaDCocoPVannucchiGA novel tyrosine kinase inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptakeJ Clin Endocrinol Metab2007923531353417595247
   PubMed Web of Science ®Google Scholar
• TamaskarIBukowskiRElsonPThyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenibAnn Oncol20081926526817962201
   PubMed Web of Science ®Google Scholar
• TorinoFCorselloSLongoRHupothyroidism related to tyrsoine kinase inhibitors: an emerging toxic effect on targeted therapyNat Rev Clin Oncol2009621922819333228
   PubMed Web of Science ®Google Scholar
• de GrootJWZonnenbergBAPlukkerJTvan Der GraafWTLinksTPImatinib induces hypothyroidism in patients receiving levothyroxineClin Pharmacol Ther20057843343816198662
   PubMed Web of Science ®Google Scholar
• MustjokiSEkblomMArstilaTPClonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapyLeukemia2009231398140519295545
   PubMed Web of Science ®Google Scholar
• SantachiaraRMaffeiRMartinelliSDevelopment of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumorHaematologica2008931252125518519520
   PubMed Web of Science ®Google Scholar
• SennLKovacsovicsTTarrPEMeylanPPeritoneal tuberculosis after imatinib therapyArch Intern Med200916931231319204223
   PubMedGoogle Scholar
• OgasawaraMMatsukawaTKatsuraYImatinib impairs the function of human regulatory T cells (Tregs) and reverses the inhibition of immune responses to imatinib-resistant CML cells by TregsASH Meeting Proceedings20091211144728
   Google Scholar
• Van GlabbekeMVerweijJCasaliPGPredicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG)Eur J Cancer2006422277228516876399
   PubMed Web of Science ®Google Scholar
• LarsonRADrukerBJGuilhotFImatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS studyBlood20081114022402818256322
   PubMed Web of Science ®Google Scholar
• BrouardMSauratJHCutaneous reactions to STI571N Engl J Med200134561861911529225
   PubMed Web of Science ®Google Scholar
• HsiaoLTChungHMLinJTStevens-Johnson syndrome after treatment with STI571: a case reportBr J Haematol200211762062212028031
   PubMed Web of Science ®Google Scholar
• NelsonRPJrCornettaKWardKEDesensitization to imatinib in patients with leukemiaAnn Allergy Asthma Immunol20069721622216937754
   PubMed Web of Science ®Google Scholar
• ParkMAVolcheckGWGuarderasJCSuccessful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literatureAllergy Asthma Proc20042534534715603208
   PubMed Web of Science ®Google Scholar
• RuleSAO’BrienSGCrossmanLCManaging cutaneous reactions to imatinib therapyBlood20021003434343512412577
   PubMed Web of Science ®Google Scholar
• GambillaraELaffitteEWidmerNSevere pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemiaDermatology200521136336516286749
   PubMed Web of Science ®Google Scholar
• SeverinoGChillottiCDe LisaRAdverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumorsAnn Pharmacother20053916216415546944
   PubMed Web of Science ®Google Scholar
• RaananiPGoldmanJMBen-BassatIChallenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571J Clin Oncol20022086987011821474
   PubMed Web of Science ®Google Scholar
• ValeyrieLBastuji-GarinSRevuzJAdverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patientsJ Am Acad Dermatol20034820120612582389
   PubMed Web of Science ®Google Scholar
• AroraBKumarLSharmaAPigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylateAnn Oncol20041535835914760137
   PubMed Web of Science ®Google Scholar
• EtienneGCony-MakhoulPMahonFXImatinib mesylate and gray hairN Engl J Med200234744644712167692
   PubMed Web of Science ®Google Scholar
• TalpazMSilverRTDrukerBJImatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyBlood2002991928193711877262
   PubMed Web of Science ®Google Scholar
• LinNUSarantopoulosSStoneJRFatal hepatic necrosis following imatinib mesylate therapyBlood20031023455345614568907
   PubMed Web of Science ®Google Scholar
• FerreroDPoglianiEMRege-CambrinGCorticosteroids can reverse severe imatinib-induced hepatotoxicityHaematologica2006913537
   Web of Science ®Google Scholar
• OhnishiKSakaiFKudohSTwenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylateLeukemia2006201162116416598305
   PubMed Web of Science ®Google Scholar
• RoyLGuilhotJMartineauGLarchéeRGuilhotFUnexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemiaLeukemia2005191689169216015386
   PubMed Web of Science ®Google Scholar
• PilotPRSablinskaKOwenSHatfieldAEpidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinibLeukemia20062014816292349
   PubMed Web of Science ®Google Scholar
• CortesJO’DwyerMEClonal evolution in chronic myelogenous leukemiaHematol Oncol Clin North Am20041867168415271399
   PubMed Web of Science ®Google Scholar
• TerreCEclacheVRousselotPReport of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemiaLeukemia2004181340134615190256
   PubMed Web of Science ®Google Scholar
• MedinaJKantarjianHTalpazMChromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phaseCancer2003981905191114584073
   PubMed Web of Science ®Google Scholar
• KovitzCKantarjianHGarcia-ManeroGAbruzzoLVCortesJMyelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemiaBlood20061082811281316809614
   PubMed Web of Science ®Google Scholar
• JabbourEKantarjianHMAbruzzoLVChromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phaseBlood20071102991299517625066
   PubMed Web of Science ®Google Scholar
• EbnöetherMStentoftJFordJBuhlLGratwohlACerebral edema as a possible complication of treatment with imatinibLancet20023591751175212049868
   PubMed Web of Science ®Google Scholar
• GoldmanJMMughalTIChronic Myeloid LeukemiaHoffbrandTuttenhamCatovskyOxford, UKBlackwell Science2005
   Google Scholar
• ValsamisHAAntiepileptic drugs and bone metabolismNutr Metab2006336doi:10.1186/1743-7075-3-36.
   Google Scholar